The Minister of Health of South Africa has announced that the price of bedaquiline will drop to just 400 USD for a 6 month treatment course effective immediately. South Africa became the first country to recommend an injection-free, bedaquiline based treatment regimen for MDR-TB patients. Originally 750 USD, this significant price drop for treatment will result in over 36 million USD in savings for the South African government over the next 8 months.
His Excellency Aaron Motsoaledi also called upon the World Health Organization to update the MDR-TB treatment guidelines in support of the evidence available to recommend bedaquiline as the new standard of treatment. This is the first step of many in ending TB.
Please click here to read the full article.
In June of 2018, South Africa began recommending bedaquiline as a routine treatment for rifampin-resistant and multidrug-resistant TB (RR/MDR-TB) patients becoming the first country to implement an injection-free treatment regimen. Now, advocates in other countries aim to follow the steps of the South African Department of Health in support of injection-free regimens.
Injectable treatments are associated with serious side effects, including irreversible hearing loss, and their efficacy against DR-TB has not been confirmed in clinical trials. TB affected communities are calling on their Ministries of Health to thus recommend bedaquiline as the standard RR-TB treatment regimen. Specifically, individuals and organizations are calling on the Indian Ministry of Health to be the next country to recommend bedaquiline.
Please click here to read the recommendations created by The Desmond Tutu Tuberculosis Centre (DTTC), the Sentinel Project on Pediatric Drug-Resistant Tuberculosis and Treatment Action Group (TAG).
Please click here to view a list of all countries where bedaquiline is currently registered.
RESIST-TB invites you to register for TAG, TB CAB, and DR-TB STAT’s webinar on Implementing a bed aquiline-based, injectable free regimen for drug-resistant tuberculosis.
On August 1, 2018 at 10AM EST, these organizations will host a critical discussion led by Dr. Nobert Ndejka from the National Department of Health in South Africa about roll-out of the unique, less toxic regimen, as his country is the first in the world to do so. Dr. Maureen Kamene from the Ministry of Health in Kenya will be talking about practical considerations when implentined BDQ-based injectable free regimens. The webinar will also include the perspective of a DR-TB survivor and other civil society members.
Please click here to register. Login information available after registration.
Closed captioning available.
South Africa’s department of health on Monday became the first one in the world to announce rolling out a new and much more tolerable drug to fight multidrug-resistant tuberculosis (MDR-TB). South Africa was the first to take this “positive step” towards making sure nobody would be denied access to the most suitable drug.
Up until now‚ injectables have been used – but they are notorious for their vicious side effects. It was announced that the new drug‚ bedaquiline‚ would replace current treatment regimens for adolescents and adults‚ from the start of their treatment. The new drug had been rolled out in small pockets across the country‚ but this scale-up is likely to reduce the burden of the disease exponentially.
Read the full article here.
The Union and RESIST-TB invite you to join an exciting webinar on Thursday, June 7th from 08:00 – 09:00 EST (14:00 – 15:00 CET and SAST) to review the results of the 2017-2018 DR-TB Working Group Survey regarding the global rollout of the 9-month TB regimen and the use of bedaquiline and delamanid for MDR-TB treatment. This discussion will cover the results of the 2018 survey, compare these to the results of the 2017 survey, and explore the current barriers to progress related to the rollout of these regimens. Please join DR-TB WG Co-Chairs Robert Horsburgh, Chen-Yuen Chiang, and Arnaud Trebucq to hear about global progress in implementing these regimens.
Please read the below information on how to register to receive connection details for this webinar.
To join the event as an attendee
1. Go to https://attendee.gotowebinar.com/register/5471390152498883843
2. Fill out the required fields and click the “Register” button at the bottom of the page.NOTE: If you are member of the Union, please enter your CU- membership ID in the designated field. If you are NOT a member of the Union, please leave this field blank. For future Union presentations, registration will require Union membership.
After you have registered for the event, you will receive a follow-up email from the Union with the link and instructions to join the webinar.
To contact your host, RESIST-TB, please send a message to firstname.lastname@example.org.
IMPORTANT NOTICE: This WebEx service includes a feature that allows audio and any documents and other materials exchanged or viewed during the session to be recorded. By joining this session, you automatically consent to such recordings. If you do not consent to the recording, discuss your concerns with the meeting host prior to the start of the recording or do not join the session. Please note that any such recordings may be subject to discovery in the event of litigation.
The informal settlement of Khayelitsha in Cape Town is the latest site of a multi country trial that aims to transform the treatment for drug-resistant tuberculosis (DR-TB). The endTB clinic was officially opened by Doctors Without Borders (MSF) and the City of Cape Town and will test five new drug regimens in Peru, Lesotho, Kazakhstan, Georgia and South Africa.
If the trial proves successful, it will be a major revolution in the treatment of the age-old disease. But it won’t be the first. There have been several over the past 100 years and we’ve come a long way. But the fact that the current treatment can only be administered by injection, and that nearly two thirds of people who are treated go deaf, elegantly explains why we’ve still got a long way to go.
There’s reason for optimism. Over the last 20 years I’ve seen a dramatic change in attitude towards people with drug resistant TB – from the World Health Organisation (WHO) right down to health workers in the smallest clinic. This gives me great hope that we’re on the right track to institutionalising care that has the patient at the very centre.
Read the full article here.
The International Journal of Tuberculosis and Lung Disease has released its May publication featuring RESIST-TB Steering Committee members Dr. C. Robert Horsburgh and Dr. Carole Mitnick as guest editors. The issue also features articles written by a number of RESIST-TB members and partners. Please see a full list of articles below:
Community engagement for paediatric MDR-TB clinical trials: principles to support ethical trial implementation
Hoddinott G, Staples S, Brown R, Simwinga M, Mubekapi-Musadaidzwa C, Hesseling AC, Hendricks G, De Koker P, McKenna L
Conducting efficacy trials in children with MDR-TB: what is the rationale and how should they be done?
Seddon JA, Weld ED, Schaaf HS, Garcia-Prats AJ, Kim S, Hesseling AC
Statistical considerations for pediatric multidrug-resistant tuberculosis efficacy trials
Kim S, Seddon JA, Garcia-Prats AJ, Montepiedra G
Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children
Garcia-Prats AJ, Svensson EM, Weld ED, Schaaf HS, Hesseling AC
Preclinical tools for the evaluation of tuberculosis treatment regimens for children
Tucker EW, Dooley KE
The burden of multidrug-resistant tuberculosis in children
Jenkins HE, Yuen CM
MDR-TB in children: back to the basics
Horsburgh CR, Gupta A
The International Journal of Tuberculosis and Lung Disease has released its May publication featuring RESIST-TB Steering Committee Members C. Robert Horsburgh and Carole Mitnick as Guest Editors. This issue also features a supplemental publication by C. Robert Horsburgh and Amita Gupta titled, “MDR-TB in Children: Back to the Basics.”
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
To view the IJTLD May issue, click here.
To read “MDR-TB in Children: Back to the Basics,” click here.